

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/M.N./	A1	2003/0113320	6/19/03	Ruosahti <i>et al.</i>	424	143.1	10/03/02
	A2	2001/0046498	11/29/01	Rouslahti <i>et al.</i>	424	178.1	1/17/01
	A3	4,472,509	9/18/84	Gansow and Strand	436	548	6/07/82
	A4	4,912,040	3/27/90	Kaufman and Dorner	435	69.6	2/03/87
	A5	4,931,053	06/05/90	L'Esperance, Jr.	606	2	01/27/88
	A6	5,021,236	6/04/91	Gries <i>et al.</i>	424	9	3/02/87
	A7	5,081,034	1/14/92	Bevilasqua <i>et al.</i>	435	252.33	11/14/88
	A8	5,098,833	03/24/92	Lasky <i>et al.</i>	435	69.1	2/23/89
	A9	5,188,964	2/23/93	McGuire <i>et al.</i>	436	64	4/12/90
	A10	5,196,523	3/23/93	Lee	536	23.5	5/19/89
	A11	5,206,347	4/27/93	Ruosahti <i>et al.</i>	530	413	7/13/90
	A12	5,216,131	6/01/93	Lasky <i>et al.</i>	435	69.1	2/23/89
	A13	5,223,409	6/29/93	Ladner <i>et al.</i>	435	69.7	3/01/91
	A14	5,225,538	7/06/93	Capon <i>et al.</i>	530	387.3	12/16/91
	A15	5,259,380	11/09/93	Mendes <i>et al.</i>	607	115	11/15/90
	A16	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	8/17/92
	A17	5,288,846	2/22/94	Quertermous <i>et al.</i>	435	172.3	8/03/92
	A18	5,304,640	4/19/94	Asky <i>et al.</i>	536	23.5	2/13/92
	A19	5,415,874	5/16/95	Bender <i>et al.</i>	424	520	10/31/89
	A20	5,428,130	6/27/95	Capon <i>et al.</i>	530	350	12/08/92
	A21	5,453,362	9/26/95	Lamarco <i>et al.</i>	435	69.1	4/12/93
V	A22	5,463,026	10/31/95	Nakamura and Sato	530	387.3	2/24/94
	A23	5,464,436	11/07/95	Smith	607	89	04/28/94

25716066.1

EXAMINER: /Meera Natarajan/

DATE CONSIDERED: 10/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/M.N./	A24	5,492,807	2/20/96	Santi	435	5	11/19/93
	A25	5,506,126	4/09/96	Seed et al.	435	172.3	1/18/93
	A26	5,536,814	7/16/96	Ruoslahti et al.	530	329	3/11/94
	A27	5,585,277	12/17/96	Bowie et al.	436	518	03/21/95
	A28	5,622,699	4/22/97	Ruoslahti et al.	424	93.6	9/11/95
	A29	5,670,312	9/23/97	Santi	435	5	11/17/95
	A30	5,688,692	11/18/97	Jat et al.	435	354	2/11/93
	A31	5,688,935	11/18/97	Stephens et al.	536	23.1	5/03/95
	A32	5,705,610	1/06/98	Zuckerman et al.	530	338	10/01/93
	A33	5,750,344	5/12/98	Doyle	435	6	10/04/95
	A34	5,840,841	11/24/98	Zuckerman et al.	530	338	5/08/97
	A35	5,866,759	2/02/99	Jat et al.	800	3	7/02/97
	A36	5,902,598	5/11/99	Chen and Ashton	424	423	8/28/97
	A37	5,955,572	9/21/99	Ruoslahti and Pasqualini	530	317	5/14/98
	A38	6,057,098	05/02/00	Buechler et al.	435	6	04/04/97
	A39	6,068,829	5/30/00	Ruoslahti and Pasqualini	242	9.1	6/23/97
	A40	6,093,800	7/25/00	Reiter et al.	530	350	9/5/97
	A41	6,174,861	1/16/01	O'Reilly and Folkman	514	12	7/07/99
	A42	6,184,973	02/06/01	Baer et al.	356	36	04/10/98
	A43	6,215,550	04/10/01	Baer et al.	356	36	07/23/98
	A44	6,232,440	5/15/01	Hillman et al.	530	350	4/20/99
	A45	6,261,789	7/17/01	Reiter et al.	435	7.23	2/17/99
▼	A46	6,271,196	08/07/01	O'Brien	514	2	03/05/96

25716066.1

EXAMINER: /Meera Natarajan/

DATE CONSIDERED: 10/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
U.S. Patent Documents <i>See Page 1-3</i>		Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/M.N./	A47	6,350,855	2/26/02	Tobin	530	350	9/15/97
	A48	6,372,720	4/16/02	Longmuir <i>et al.</i>	514	44	2/5/98
	A49	6,399,384	6/04/02	Jat	435	456	9/15/00
	A50	6,458,381	10/01/02	Sourovci and Jung	424	450	2/12/97
	A51	6,528,281	3/04/03	Tobin	435	69.1	6/14/96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 99/47554	9/23/99	WIPO	English
	B2	WO 02/020723	3/14/02	WIPO	English
	B3	WO 02/20822	3/14/02	WIPO	English
	B4	WO 03/022991	3/20/03	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Arap <i>et al.</i> , "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> , 279:377-380, 1998.
	C2	Arap <i>et al.</i> , "Chemotherapy targeted to tumor vasculature," <i>Curr. Opin. Oncol.</i> , 10:560-565, 1998.
	C3	Arap <i>et al.</i> , "Steps toward mapping the human vasculature by phage display." <i>Nature Med.</i> , 8:121-127, 2002.
	C4	Barrow and Soothill, "Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential," <i>Trends Microbiol.</i> , 5:268-271, 1997.
V	C5	Bergelson <i>et al.</i> , "Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5," <i>Science</i> , 275:1320-1323, 1997.

25716066.1

EXAMINER: /Meera Natarajan/	DATE CONSIDERED: 10/23/2007
-----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.N./	C6	Brawn <i>et al.</i> , "Prostatic Acid Phosphatase Levels (Enzymatic Method) From Completely Sectioned, Clinically Benign, Whole Prostates," <i>The Prostate</i> , 28:295-299, 1996.
	C7	Burg <i>et al.</i> , "NG2 Proteoglycan-binding Peptides Target Tumor Neovasculature," <i>Cancer Res.</i> , 59:2869-2874, 1999.
	C8	Campbell <i>et al.</i> , "Increased Expression of the Interleukin-11 Receptor and Evidence of STAT3 Activation in Prostate Carcinoma." <i>Am. J. Pathol.</i> , 158:25-32, 2001.
	C9	Chen <i>et al.</i> , "Thapsigargin-induced grp78 expression is mediated by the increase of cytosolic free calcium in 9L rat brain tumor cells," <i>J. Cell. Biochem.</i> , 78:404-416, 2000.
	C10	Choongkittaworn <i>et al.</i> , "Expression of prohibitin in rat seminiferous epithelium," <i>Biol. Reprod.</i> , 49(2):300-310, 1993.
	C11	Curnis <i>et al.</i> , "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)," <i>Nat Biotechnol.</i> , (11):1185-90, 2000.
	C12	Database NCBI on STN, Accession Number G69514, Klenk <i>et al.</i> , "The Complete Genome Sequence of the Hyperthermophilic, Sulphate-reducing Archaeon <i>Archaeoglobus fulgidus</i> ," <i>Nature</i> , 390:364-370, 1997.
	C13	Database NCBI on STN, Accession Number T21276, Matthews <i>et al.</i> , "Direct Submission," 1999.
	C14	Delpino <i>et al.</i> , "Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin," <i>Mol. Membr. Biol.</i> , 15(1):21-26, 1998.
	C15	Ellerby <i>et al.</i> , "Anti- cancer activity of targeted pro-apoptotic peptides," <i>Nature Med.</i> , 5:1032-1038, 1999.
	C16	Giannakouros <i>et al.</i> , "Post-translational Processing of <i>Schizosaccharomyces pombe</i> YPT5 Protein: In Vitro and In Vivo Analysis of Processing Mutants," <i>Journal of Biological Chemistry</i> , 268:24467-24474, 1993.
↓	C17	Grifman <i>et al.</i> , "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids," <i>Mol. Ther.</i> , 3(6):964-975, 2001.
	C18	Harrington <i>et al.</i> , "Gene Therapy for prostate cancer: current status and future prospects," <i>J. Urol.</i> , 166:1220-1233, 2001.

25716066.1

EXAMINER: <i>/Meera Natarajan/</i>	DATE CONSIDERED: 10/23/2007
---------------------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.N./	C19	Hong <i>et al.</i> , "Adenovirus type 5 fiber knob binds to MHC class I alpha-2 domain at the surface of human epithelial and B lymphoblastoid cells," <i>EMBO J.</i> , 16:2294-2306, 1997.
	C20	Huang <i>et al.</i> , "Comparison of Prostate Secretory Protein With Prostate Specific Antigen and Prostatic Acid Phosphatase as a Serum Biomarker for Diagnosis and Monitoring Patients With Prostate Carcinoma," <i>Prostate</i> , 23:201-212, 1993.
	C21	Ikonen <i>et al.</i> , "Prohibitin, an antiproliferative protein, is localized to mitochondria," <i>FEBS Letters</i> , 358(3):273-277, 1995.
	C22	Ino <i>et al.</i> , "Expression of aminopeptidase A in human gestational choriocarcinoma cell lines and tissues," <i>Placenta</i> , 21:63-72, 2000.
	C23	Koivunen <i>et al.</i> , "Inhibition of Beta(2) Integrin-mediated Leukocyte Cell Adhesion by Leucine-Leucine-Glycine Motif-containing Peptides." <i>J. Cell Biol.</i> , 153:905-915, 2001.
	C24	Koivunen <i>et al.</i> , "Tumor targeting with a selective gelatinase inhibitor," <i>Nature Biotechnol.</i> , 17:768-774, 1999a.
	C25	Larocca <i>et al.</i> , "Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage," <i>FASEB J.</i> , 13:727-734, 1999.
	C26	Mahboubi <i>et al.</i> , "IL-11 Activates Human Endothelial Cells to Resist Immune-Mediated Injury," <i>J. Immunol.</i> , 164:3837-3846, 2000.
	C27	Melnick and Argon, "Molecular chaperones and the biosynthesis of antigen receptors." <i>Immunol. Today</i> , 16:243-250, 1995.
	C28	Misra <i>et al.</i> , "The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for, GRP 78-mediated signal transduction," <i>J Biol Chem.</i> , 277(44):42082-7, 2002.
	C29	Murphy <i>et al.</i> , "Evaluation and Comparison of Two New Prostate Carcinoma Markers. Free-Prostate Specific Antigen and Prostate Specific Membrane Antigen." <i>Cancer</i> , 78:809-818, 1996.
	C30	O'Dowd <i>et al.</i> , "Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer," <i>J. Urol.</i> , 158:687-698, 1997.
▼	C31	Pasqualini and Ruoslahti, "Organ targeting <i>in vivo</i> using phage display peptide libraries," <i>Nature</i> 380:364-366, 1996.

25716066.1

EXAMINER: /Meera Natarajan/

DATE CONSIDERED: 10/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Wadih Arap, et al.	
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.N./	C32	Pasqualini <i>et al.</i> , "Aminopeptidase N I a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis," <i>Cancer Res.</i> , 60:722-727, 2000.
	C33	Pasqualini, "Vascular targeting with phage peptide libraries," <i>The Quart. J. Nucl. Med.</i> , 43:159-162, 1999.
	C34	Piironen <i>et al.</i> , "Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum." <i>Clin. Chem.</i> , 42:1034-1041, 1996.
	C35	Poul and Marks, "Targeted Gene Delivery to Mammalian Cells by Filamentous Bacteriophage," <i>J. Mol. Biol.</i> , 288:203-211, 1999.
	C36	Raisler <i>et al.</i> , "Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization," <i>Proc. Natl. Acad. Sci.</i> , 99:8909-8914, 2002.
	C37	Rajotte and Ruoslahti, "Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by <i>In Vivo</i> Phage Display," <i>J Biol Chem.</i> , 274:11593-11598, 1999.
	C38	Rajotte <i>et al.</i> , "Molecular Heterogeneity of the Vascular Endothelium Revealed by <i>In Vivo</i> Phage Display," <i>J Clin. Invest.</i> , 102:430-437, 1998.
	C39	Ruoslahti, "RGD And Other Recognition Sequences For Integrins," <i>Annu. Rev. Cell Dev. Biol.</i> , 12:697-715, 1996.
	C40	Shi <i>et al.</i> , "Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth <i>in vivo</i> ," <i>Cancer Gene Therapy</i> , 9:513-521 (2002)
	C41	Smith and Scott, "Libraries of Peptides and Proteins Displayed on Filamentous Phage," <i>Meth. Enzymol.</i> , 217:228-257, 1993.
	C42	Trepel <i>et al.</i> , "Molecular Adaptors for Vascular-Targeted Adenoviral Gene Delivery," <i>Hum. Gene. Ther.</i> , 11:1971-1981, 2000.
	C43	Tsimanis <i>et al.</i> , "Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia," <i>Leuk. Lymphoma</i> , 42(1-2):195-205, 2001.
↓	C44	Veltri <i>et al.</i> , "Interleukin-8 Serum Levels in Patients With Benign Prostatic Hyperplasia and Prostate Cancer," <i>Urology</i> , 53:139-147, 1999.

25716066.1

EXAMINER: /Meera Natarajan/

DATE CONSIDERED: 10/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:857US	Serial No. 10/530,168
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT <small>(Use several sheets if necessary)</small>			
		Filing Date: April 4, 2005	Group: 1643
U.S. Patent Documents <i>See Page 1-3</i>	Foreign Patent Documents <i>See Page 3</i>	Other Art <i>See Page 3-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/M.N./	C45	Vendruscolo <i>et al.</i> , "Three key residues form a critical contact network in a protein folding transition state," <i>Nature</i> , 409:641-45, 2001.
/M.N./	C46	Wang <i>et al.</i> , "Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function," <i>Oncogene</i> , 18(23):3501-3510, 1999.
/M.N./	C47	Weitzman <i>et al.</i> , "Adenovirus Vectors in Cancer Gene Therapy," In: <i>Gene Therapy Technology and Vector Systems</i> , 2:17-25, 1997.
/M.N./	C48	Wickham, "Targeting adenovirus," <i>Gene Ther</i> , 7:110-114, 2000.
/M.N./	C49	Zhang, "Development and application of adenoviral vectors for gene therapy of cancer," <i>Cancer Gene Ther.</i> , 6:113-138, 1999.

25716066.1

EXAMINER: /Meera Natarajan/

DATE CONSIDERED: 10/23/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.